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Introduction: Ulcerative colitis (UC) presents as proctitis in approximately a
quarter of the patients. It may progress into left-sided or extensive colitis in
up to 50% of cases upon long-term follow-up.
Areas covered: Currently available data on ulcerative proctitis are summa-
rized and critically reviewed. Extensive literature search (MEDLINE) was
performed to identify relevant articles up to March 2014.
Expert opinion: The short-term goal of the treatment in UC is to induce
remission, whereas long-term goals are to maintain remission and prevent dis-
ease progression. Topically administered 5-aminosalicylates (5-ASA) and corti-
costeroids are effective in the treatment of proctitis, although they seem to
be underused in everyday practice. Locally administered 5-ASA preparations
are more effective than oral compounds. The combination of topical and
oral 5-ASA and steroids should be considered for escalation of treatment.
Refractory patients should be re-evaluated to exclude for compliance failures,
infections or proximal disease extent. True refractory or steroid-dependent
patients may require immunomodulators or biological therapy. Alternative
medicine can be used complementarily, while experimental approaches are
reserved for patients failing conventional medication. Proctocolectomy may
be the last resort of treatment. Upon long-term, 5-ASA maintenance treat-
ment is indicated in all UC cases to prevent relapse and disease progression.
Keywords: azathioprine, infliximab, steroids, therapy, ulcerative colitis, ulcerative proctitis,
5-aminosalicylates
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1. Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two main types of chronic
inflammatory bowel diseases (IBD). UC is considered to develop due to a dysregu-
lated immune response against the commensal gut microflora in a genetically
predisposed individual [1]. Although, the precise trigger of the disease is unknown,
the common final pathway is a vicious circle of mucosal inflammation and
disrupted epithelial barrier function [1]. UC is characterized by colonic inflamma-
tion limited to the mucosa. It typically involves the rectum and may extend proxi-
mally in a continuous fashion. Depending on disease extent, UC can be classified as
proctitis (E1, inflammation limited to the rectum), left-sided colitis (E2, inflamma-
tion terminating at the splenic flexure) or extensive colitis (E3) according to the
Montreal classification [2]. However, some patients with proctitis or left-sided colitis
may also exhibit a caecal patch of inflammation [3].
Incidence rates for UC vary from 0.5 to 24.5 per 100,000 person-years
worldwide [4]. Approximately, a quarter of UC patients present with proctitis at
the time of diagnosis [5]. In comparison, left-sided colitis is the initial diagnosis in
half of the patients and extensive colitis in another quarter of the patients [5]. Impor-
tantly, upon 5-year follow-up proximal extension of ulcerative proctitis (UP) may
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occur in 20 -- 28% of the patients, with 4 -- 10% progressing
to extensive colitis [6,7]. Long-term epidemiological studies
show that up to half of the proctitis patients exhibit proximal
disease extension 10 years after diagnosis [7-10]. Furthermore,
the probability for disease progression was 53% upon 25 years
of patients’ follow-up [9]. Increased disease severity upon diag-
nosis, as indicated by both the endoscopic and total Mayo
score, and corticosteroid use were associated with disease
extension. Additionally, chronic, continuous and relapsing
disease courses were also related to extension of mucosal
inflammation [8]. Evidence suggests that prolonged oral
mesalazine treatment may prevent proximal spread of rectal
inflammation, while topical therapy prevents disease
relapse [11,12]. Therefore, while the short-term goal of treat-
ment in proctitis is to induce remission, long-term goals are
to maintain remission and prevent disease progression.
This article aims to review and evaluate available data on
the management of UP. Of note, only few data are available
exclusively on the treatment of UP. Studies usually include
patients with proctitis and distal colitis without clear distinc-
tion between the two subgroups [13]. In addition, patients
with proctitis only were excluded from biological studies
focusing on UC, such as the ULTRA trial on adalimumab,
the PURSUIT trials on golimumab or the GEMINI trial on
vedolizumab [14-17].
2. Management of ulcerative proctitis
2.1 Active proctitis
2.1.1 Formulation and delivery
Rectally administered topical agents represent the first-line
therapeutic option in proctitis, as they directly target the site
of inflammation when sufficient contact time is allowed to
reach effective mucosal drug concentration. In addition, side
effects are uncommon, as they are rarely associated with
significant serum concentrations. Drug formulations such as
suppository, foam and enema enable optimized delivery to
the affected mucosa. Suppositories seem to be more appropri-
ate than enemas in the treatment of proctitis, as although the
latter may reach the splenic flexure, its maximum spread is
localized from 11 to 40 cm from the anal verge [18,19]. Liquid
and foam mesalazine enemas seem to be equally effective in
the treatment of left-sided colitis and proctitis [20].
Delivery systems of oral 5-aminosalicylate (5-ASA) com-
pounds can be divided into azo-compounds, controlled
release, pH-dependent (either pH6 or pH7) and composite
(pH-dependent combined with controlled release) types [21].
Although data are abundant on different delivery systems,
yet evidence for difference in efficacy is weak.
2.1.2 5-Aminosalicylates
Topical 5-ASA-induced remission in active proctitis and distal
colitis was 31 -- 80% (median 67%) compared with 7 -- 11%
in patients given placebo in a meta-analysis of 11 trials includ-
ing 778 patients [22]. Single dose of mesalazine suppository 1 g
daily was shown to be equally effective and better tolerated
than mesalazine 500 mg suppository twice (b.i.d.) or thrice
daily (t.i.d.) [23,24]. Daily dose of 1 g mesalazine suppository
seems optimal, and no dose response has been observed with
regard to topical treatment [25]. According to a recent multi-
centre, randomized, double-blind, placebo-controlled study,
endoscopic remission rates after 4 weeks of treatment with
1 g mesalazine or placebo suppository were 83.8% versus
36.1% (p < 0.0001) [26]. The percentage of patients without
rectal bleeding was significantly higher already after the third
day of treatment [26]. In comparison with topical steroids, top-
ical mesalazine proved to be more effective in terms of clinical
symptoms (OR = 2.42, 95%CI: 1.72 -- 3.41), endoscopy
(OR = 1.89, 95%CI: 1.29 -- 2.76) or histology (OR = 2.03,
95%CI: 1.28 -- 3.20) [27].
Oral 5-ASAs are less effective than topical 5-ASAs in treating
proctitis, which may be due to the rapid transit and decreased
contact time with the inflamed mucosa, and the relatively low
concentration of the drug reaching the rectum [28,29]. However,
oral 5-ASAs seem to be associated with better patient compli-
ance. A recent Cochrane review showed that mesalazine exhib-
its the same therapeutic benefit in UC as its prodrug,
sulfasalazine, in inducing remission and is better tolerated by
patients [30]. The rate of adverse events was 29% in the
sulfasalazine-treated patients compared with 15% in the
mesalazine-treated patients (relative risk 0.48, 95% CI
0.37 -- 0.63) [30]. Sulfasalazine is associated with side effects
such as nausea, vomiting, abdominal pain, fever, skin rash,
neutropenia, male infertility, folate deficiency, neuropathy,
autoimmune haemolysis and rarely with nephrotoxicity,
hepatotoxicity or pancreatitis. Once-daily dosing of 5-ASA
(2 g/day) was shown to be as efficacious as conventional
dosing and may also result in improved adherence [30,31]. In
Article highlights.
. The short-term goal of treatment in proctitis is to induce
remission, whereas long-term goals are to maintain
remission and prevent disease progression.
. In mild proctitis topical 5-ASA, in moderate-to-severe
proctitis a combination of oral and topical 5-ASA
preparations are considered as first-line treatment. In
severe proctitis, topical and oral corticosteroids should
be considered additionally.
. Patients refractory to combined topical and systemic
5-ASA and steroid therapy should be reinvestigated for
other causes of therapeutic failure. In true refractory
patients escalation of treatment to thiopurines and
anti-TNF can be recommended.
. Proctocolectomy with ileal pouch anal anastomosis is
considered as the last resort of treatment.
. Long-term maintenance therapy is recommended. The
choice of maintenance treatment (topical and/or oral
5-ASA, thiopurines or anti-TNF) depends on previous
disease severity and response to treatment.
This box summarises key points contained in the article.
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mild-to-moderate UC, 2.4 g/day of delayed release oral mesa-
lazine (Asacol) appeared effective for induction. However,
patients with moderate disease activity may benefit from a
higher dose of 4.8 g as shown by the ASCEND trials [32-34].
There have been no dedicated trials to evaluate combination
therapy of topical and oral mesalazine in proctitis. However,
combination therapy induces faster relief of symptoms and sig-
nificantly greater change in the Disease Activity Index than
either topical or oral mesalazine alone for colitis extending no
more than 50 cm from the anal verge [35].
2.1.3 Corticosteroids
Rectally administered corticosteroids are also effective in
inducing remission in UP [36]. Rapidly metabolizing cortico-
steroids with low systemic bioavailability result in reduced
adrenal suppression compared to prednisolone enemas [37].
Budesonide enemas were significantly more effective than pla-
cebo and comparable to 5-ASA enemas in inducing remis-
sion [36,38]. Other high glucocorticoid potency and low
bioavailability steroids, such as beclomethasone dipropionate
enemas showed similar efficacy to prednisolone and to topi-
cally administered 5-ASA in improving the symptoms and
inducing remission [37,39].
Combination of topical mesalazine and steroid treatment
may be of benefit. Beclomethasone dipropionate (3 mg) and
mesalazine (2 g) enemas produced significantly better clinical,
endoscopic and histological results than either agent alone [40].
Patients who fail to improve on a combination therapy of
topical and oral 5-ASA and topical corticosteroids should be
treated with oral prednisolone (40 mg/day for 1 week, reduc-
ing 5 mg/day every week) [41-43]. In patients with persisting
active UC after oral steroid and 5-ASA treatment, remission
was achieved within a week in 90%, by intensive intravenous
steroid treatment [44]. Methylprednisolone 60 mg/24 h or
hydrocortisone 100 mg four times daily are used as intrave-
nous corticosteroids for a maximum of 7 -- 10 days [43].
Although systemic corticosteroids have been widely used
in the treatment of UC for the past 60 years, no studies
evaluated their application in proctitis.
Interestingly, despite all convincing evidence for topical
treatment of proctitis, it seems to be underused in everyday
practice. In a Swiss cohort, only 39% of patients received
topical therapy with 5-ASA or corticosteroids either in
monotherapy or in combination with systemic treatment for
remission induction [45].
3. Re-evaluation
In patients who fail to respond to topical and systemic 5-ASA
and topical and oral corticosteroids, alternative causes of
therapy failures should be investigated prior to escalation of
therapy. Non-adherence to therapy was reported by 38.9%
of IBD patients and was irrespective of medication type or
disease activity [46]. Colitis due to hypersensitivity to 5-ASA
may also mimic a flare and is difficult to distinguish. Proximal
disease extension and superinfections predisposing to that,
such as Clostridium difficile and cytomegalovirus (CMV)
should be ruled out. Alternative explanations may also include
inappropriate diagnosis, such as irritable bowel syndrome,
CD, mucosal prolapse or cancer. Other rare causes including
proctitis cystica profunda or sexually transmitted infections,
such as herpetic, gonococcal or syphilitic proctitis should
also be considered.
4 True therapy-refractory and steroid-
dependent proctitis
True therapy-refractory cases can be extremely challenging to
manage. Options mainly include thiopurines and anti-TNF
agents. Salvage medical therapies may also include intrave-
nous or oral cyclosporine or oral or rectal tacrolimus [47]. If
not acutely ill, the patient may benefit from alternative
therapies, whose efficacy is based on small open-label trials.
4.1 Thiopurines
There are no prospective dedicated trials to evaluate the effect
of thiopurines in UC. A recent retrospective study, however,
indicated that in steroid-dependent patients administration
of azathioprine (AZA) resulted in significantly higher thera-
peutic success (71.2%) compared to patients with AZA intol-
erance (25.0%, p < 0.001) upon long-term follow-up [48].
Additionally, a recent trial randomized moderate-to-severe
UC patients to receive AZA (2.5 mg/kg), infliximab (regular
dosing regimen) or AZA and infliximab combination therapy.
Corticosteroid-free remission at week 16 was achieved by
39.7% of patients receiving combination therapy compared
with 22.1% receiving infliximab (p = 0.017) and 23.7%
receiving AZA monotherapy (p = 0.032) [49].
4.2 Anti-TNF
In the ACT 1 and 2 trials on infliximab, 55% of patients had
left-sided or distal colitis [13]. Although no separate subgroup
analysis was carried out, two-thirds of UC patients failing
5-ASAs, steroids or thiopurines responded to regular inflixi-
mab dosing regimen [13]. A recent small retrospective cohort
focusing on the efficacy of infliximab in therapy-refractory
proctitis patients showed that infliximab-induced clinical
response in 69% and remission in about 30% of patients [50].
Notably, patients with UP were excluded from most anti-
TNF prospective randomized controlled trials [14-17]. There-
fore, currently infliximab has the most available evidence on
anti-TNF treatment of proctitis.
4.3 Salvage therapy
Intravenous cyclosporine (2 -- 4 mg/kg/d) is also effective in
patients failing intravenous corticosteroids; however, its use
is limited by side effects [47]. Cyclosporine enema was not
more efficient than placebo in active left-sided colitis [51].
Two pilot studies evaluated the effect of locally administered
tacrolimus ointment, suppository or enema in UP and distal
Update on proctitis therapy
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colitis [52,53]. Two-thirds of the patients had clinical improve-
ment after 4 -- 8 weeks of topical tacrolimus treatment. In a
large retrospective chart review, which included 18 patients
with proctitis, oral tacrolimus was efficient in steroid-
refractory cases [54]. However, in contrast to potential toxicity
of systemic administration, tacrolimus trough levels were low
after local administration and side effects were reported by
none of the patients [53]. Topically administered infliximab
was also shown to be effective in a refractory case previously
unresponsive to intravenous induction treatment [55].
4.4 Experimental treatment
Rebamipide, an agent suppressing neutrophil function and
stimulating epithelial cell regeneration, induced significant
clinical, endoscopical and histological improvement when
administered as enemas in patients with proctitis or distal
colitis [56]. Case series have shown that elective appendectomy
can be associated with clinical improvement or complete
resolution of symptoms [57,58]. Additionally, several topical
agents have been investigated, such as epidermal growth fac-
tor, ecabet sodium, butyrate, arsenic, ropivacaine, bismuth
subsalicylate and thromboxane [59-61]. Although some of these
agents show encouraging preliminary results, most com-
pounds were not evaluated in greater patient numbers, and
therefore, solid evidence is still lacking to suggest their use
in everyday practice.
4.5 Complementary and alternative medicine
Complementary alternative medicine (CAM) has been popular
by tradition in Asia [62]. In a recent systematic review including
14 trials on UC, aloe vera gel, Triticum aestivum (wheat grass
juice), Andrographis paniculata extract (HMPL-004) and
topical Xilei San (a Chinese herbal medicine with anti-
inflammatory effect) were superior to placebo in inducing
remission or response [63]. Additionally, curcumin was superior
to placebo in maintaining remission, while Boswellia serrata
gum resin and Plantago ovata seeds were as effective as
mesalazine [64]. Although initial results with CAM seem to be
encouraging, further trials are needed to confirm their efficacy
in large patient numbers and to encourage their use in daily
practice.
5. Surgery
Colectomy in proctitis (without disease extension) is consid-
ered in exceptional cases. The outcome of total proctocolec-
tomy with ileal pouch anal anastomosis (IPAA) formation is
good. In 263 patients who had a restorative proctocolectomy,
27 patients had surgery for distal disease and all but one patient
were satisfied with the results and most patients wished that
they had had surgery sooner [65]. However, complications,
such as cuffitis may develop, where rectal bleeding is a charac-
teristic feature. Mesalazine suppository 500 mg b.i.d. was effec-
tive in reducing clinical, endoscopical and histological activity
in cuffitis [66]. A recent cohort examined the long-term course
of cuffitis in patients after IPAA. After a median follow-up of
6 years, 33.3% of patients had 5-ASA/steroid-responsive cuffi-
tis. In patients with 5-ASA/steroid-dependent or -refractory
cuffitis, 32.8% was diagnosed with CD of the pouch and
24.1% had surgical complications [67].
6. Maintenance treatment
Only a small percentage of patients are able to discontinue
long-term therapy without disease relapse. As disease extension
and relapse can be prevented by maintenance therapy, patients
are encouraged to adhere to maintenance therapy. The length
of the recommended maintenance therapy in patients with
long-term clinical remission is, however, conflictive. Of note,
data from a US database showed that maintenance therapy is
not continued in the majority of proctitis cases. Seventy per
cent of UP patients who were initially treated with mesalazine
suppositories, and even 40 -- 50% of those patients who began
oral or systemic glucocorticosteroid, did not take further
medication after remission induction [68].
Traditionally, oral 5-ASA and sulfasalazine were used
for maintenance treatment in UC. A recent Cochrane review
reported that sulfasalazine was superior in the maintenance
setting [69]. A recent meta-analysis including seven
randomized-controlled trials (n = 555 patients) showed that
topical mesalazine was effective in preventing relapse of distal
UC [12,70]. In the study, 500 mg mesalazine b.i.d. seems to be
the most efficient therapeutic regimen for maintenance with a
cumulative relapse rate of 10% at 12 months (95% CI:
0 -- 21) [71]. However, even intermittent topical treatment is
more efficient maintenance treatment than placebo [72,73].
There are no dedicated studies to evaluate the efficacy of
rectally administered corticosteroids for the maintenance
treatment in proctitis. In the only randomized placebo-
controlled trial, oral prednisone was ineffective in maintaining
the remission induced by oral steroids at 6 months [74]. More
importantly, cumulative doses may be associated with
well-known steroid side effects.
Clinical trials showed benefit from thiopurine treatment
in UC maintenance [75]. The 1-year relapse rates were signifi-
cantly lower in patients taking AZA (36%) compared with
placebo (59%, p = 0.04) [76]. In a recent randomized clinical
trial, steroid-dependent UC patients treated with AZA
(2 mg/kg/d) had a significantly higher rate of clinical and
endoscopic remission, leading to steroids withdrawal in a
greater percentage of cases compared with patients receiving
only high-dose oral 5-ASA (53 vs 19%, p = 0.006) [77].
Finally, a randomized study suggests a favourable role of
probiotics, which was comparable to mesalamine in the
maintenance treatment in UC [78].
7. Colorectal cancer risk and surveillance
Longstanding UC is associated with increased colorectal
cancer (CRC) risk. Although risks estimates vary, it is
K.B. Gecse & P.L. Lakatos
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associated with the extent, duration and severity of mucosal
inflammation. A systematic review from the previous decade
reported a cumulative CRC risk of 2% at 10 years, 8% at
20 years and 18% at 30 years [79]. In contrast, in a most recent
meta-analysis, the cumulative CRC risk was < 1% at 10 years,
0.4 -- 2% at 15 years and 1.1 -- 5.3% at 20 years [80]. The rea-
son behind the changing trend could be multifactorial includ-
ing increased surveillance, changing treatment goals (full
mucosal healing) and possible chemopreventive effects of
5-ASA. A recent review on 5-ASA concluded that the ability
to heal colonic mucosa as well as influencing molecular path-
ways of carcinogenesis may contribute to possible chemopre-
vention [81]. With regard to disease limited to the rectum,
no increased CRC risk is reported. Therefore, according to
the recent ECCO guidelines after screening colonoscopy at
6 -- 8 years after the onset of symptoms, inclusion in a regular
surveillance colonoscopy program is not recommended in
patients without proximal extension [82].
8. Expert opinion
The short-term goal of treatment in proctitis is to induce
remission, whereas long-term goals are to maintain remission
and prevent disease progression (Figure 1). The first-line ther-
apy for active proctitis should be topical 5-ASA in line with
the results from meta-analyses of published trials show that
topical 5-ASA is superior to placebo and conventional cortico-
steroids in inducing remission. One gram once daily dosing of
5-ASA suppository has been shown to be equally effective and
better tolerated than b.i.d. or t.i.d. suppository. Short-term
remission rates may be as high as 85%. In case of suboptimal
therapeutic response to topical 5-ASA, treatment can be
extended with oral 5-ASA and/or topical steroids, as the
combination of rectal 5-ASA with a rectal corticosteroid or
oral aminosalicylate is superior to rectal 5-ASA alone [83]. Rec-
tally administered corticosteroid therapy with suppositories or
Proctitis
Mild Moderate-to-severe Severe
M
ai
nt
en
an
ce
 th
er
ap
y*
topical + oral 5-ASA
topical steroids
topical 5-ASA
oral 5-ASA
Refractory proctitis
True refractory proctitis
Re-evaluate
Compliance
IBS
Infection
Drug hypersensitivity
Proximal extension
i.v. steroids
Thiopurines/anti-TNF
Experimental therapies
Proctocolectomy + IPAA‡
topical + oral 5-ASA +
topical steroids
oral steroids
Figure 1. Treatment algorithm for patients with ulcerative proctitis.
*Depends on disease severity, induction agent and previous disease course: topical (or the combination of topical and oral) 5-ASA is recommended as first-line,
immunosuppressives should be considered in steroid dependent cases, while immunosuppressives/anti-TNFs are recommended in refractory cases.
zConsidered in exceptional cases.
5-ASA: 5-Aminosalicylates; IBS: Irritable bowel syndrome; IPAA: Ileo-anal pouch anastomosis; i.v.: intravenous.
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foam is an effective alternative for patients intolerant of or
unresponsive to 5-ASA.
In moderate-to-severe UP, a combination of oral and
topical 5-ASA-based therapy should be considered as first-
line treatment. In severe UP, oral or intravenous corticoste-
roids should be applied (at a maximum dose of prednisolone
40 -- 60 mg, or the equivalent of methylprednisolone).
Refractory proctitis represents a difficult clinical entity for
both patients and doctors. Thus, patients failing combined
topical and systemic 5-ASA and steroid therapy should be
reinvestigated for other causes of therapeutic failure, such as
co-existing IBS, patient compliance, drug hypersensitivity,
infections (e.g.,: C. difficile, CMV/bacterial superinfection)
and proximal disease extension. In patients with refractory
disease, escalation of treatment to thiopurines and anti-TNF
can be recommended [84]. UP patients with severe initial dis-
ease should be considered for more aggressive treatment from
the beginning, as they are more likely to develop disease
extension during the course of their disease.
The efficacy of alternative treatment options, including
Chinese herbal preparation, Xilai San is conflictive and
warrant further investigations. The use of other experimental
therapies (e.g., elective appendectomy or infliximab and
cyclosporine enemas, arsenic and tacrolimus suppositories)
should also be restricted for clinical trials and exceptional
cases in expert centres. Nevertheless, before these potentially
promising approaches become the routine part of the thera-
peutic armamentarium, better understanding of their mecha-
nism of action and solid evidence for their efficacy are needed.
Proctocolectomy with IPAA may be considered as ultimate
treatment in refractory proctitis cases.
Long-term maintenance treatment, especially with topical
(or oral) 5-ASA therapy is recommended. However, long-
term adherence is suboptimal. In mild proctitis cases with
long-term clinical remission, intermittent therapy or nomainte-
nance therapy is an option. In initially moderate-to-severe cases,
combined oral (1 -- 1.5 g/day) and topical 5-ASA (e.g., 1 g
5-ASA suppositories three times per week) should be the
treatment of choice even for maintenance. The risk of CRC is
not increased in UP; therefore, routine endoscopic surveillance
is not recommended.
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